Psychedelic clinical research is officially authorised in a growing number of countries across North America, Europe, Oceania, and the Middle East, where studies are conducted under strict regulatory and ethical frameworks. Countries such as the United States, Canada, the United Kingdom, Australia, Israel, Switzerland, the Netherlands, Germany, and Portugal have established pathways that allow researchers to investigate compounds such as psilocybin, MDMA, LSD, and ibogaine in approved clinical settings.
While regulations vary between jurisdictions, research institutions and sponsors are generally required to obtain ethics approval, controlled substance licences, and regulatory authorisation before conducting studies. As scientific evidence continues to emerge, an increasing number of countries are supporting psychedelic research to explore new treatments for mental health conditions, addiction, and other unmet medical needs.
